Sun Pharma’s $11.75-billion Organon deal: What it means for Indian pharma M&As

Sun Pharma’s $11.75-billion acquisition of Organon & Co. is likely to push Indian pharmaceutical companies to evaluate larger overseas acquisitions as the sector looks to expand beyond generics into specialty and branded segments, analysts said. The transaction, currently the largest biopharma deal globally in 2026, represents a turning point where Indian firms act as global consolidators rather than just manufacturers.

The all-cash deal, the largest outbound transaction by an Indian drugmaker, gives Sun Pharma access to Organon’s women’s health and specialty portfolio and a commercial presence across developed markets. The combined entity is expected to generate roughly $12.4 billion in revenue, making Sun Pharma the 7th largest biosimilar player and a Top 3 global leader in Women’s Health.

“This is a coming-of-age move… the deal raises expectations for scale and capital deployment among peers,” said Salil Kallianpur, a pharma analyst.

MUST READ: BT Explainer: Why Sun Pharma’s $11.75-bn Organon deal is priced below past pharma acquisitions

The transaction has also drawn attention for its pricing. Sun is acquiring Organon at about 6 times EV/EBITDA, lower than recent domestic transactions such as Mankind Pharma’s acquisition of Bharat Serums and Vaccines and Torrent Pharmaceuticals’ buyout of JB Chemicals, which were at over 20 times. Analysts point out that this "value arbitrage"—where global platforms are priced significantly lower than domestic targets is a major signal that Indian capital will increasingly flow toward overseas markets.

“The lower multiple reflects Organon’s debt and modest growth profile rather than a discount. The scope for value creation lies in improving performance and capturing synergies after integration,” Poornima Vardhan and Taponeel Mukherjee, analysts at AltG Investment Research Lab said.

MUST READ: Sun Pharma-Organon deal: What the $11.75 billion bet means for China, women’s health and biosimilars

The lower valuation is influenced by the fact that Organon carried roughly $8.6 billion in debt as of late 2025. Additionally, the market remains cautious regarding the upcoming "patent cliff" for Organon’s lead contraceptive product, Nexplanon.

The deal comes at a time when several Indian pharmaceutical companies have strengthened their balance sheets. Many have also increased investments in specialty therapies, complex generics and injectables, areas that require scale and access to regulated markets. Sun’s move to "buy" rather than "build" a biosimilar pipeline serves as a new blueprint for peers to bypass years of R&D.

Companies such as Dr. Reddy’s Laboratories have been building a presence in oncology and complex injectables, while Cipla has expanded its respiratory and specialty portfolio. Lupin has also been focusing on moving beyond traditional generics, particularly in the US market where pricing pressure has affected performance.

Industry observers say these companies have so far relied on smaller acquisitions and partnerships to build capabilities. The Organon deal highlights the option of acquiring established global platforms to accelerate growth in specialty segments.

MUST READ: What is the Organon deal, and why are Sun Pharma's shares falling?

“Companies with strong cash reserves, global ambitions and gaps in their portfolios are more likely to consider such acquisitions. These transactions can provide access to commercial infrastructure, differentiated products and regulated markets that are difficult to build organically,” Kallianpur said.

At the same time, consolidation within India has continued alongside overseas expansion. Deals such as Mankind Pharma’s acquisition of Bharat Serums and Vaccines and Torrent Pharmaceuticals’ buyout of JB Chemicals have focused on strengthening domestic scale and expanding into specialty therapies.

Industry observers said companies may pursue both strategies in parallel, using domestic acquisitions to strengthen market position and cash flows while exploring overseas deals to expand their global footprint. Sun Pharma’s willingness to manage a Net Debt/EBITDA of 2.3x post-deal indicate that Indian leadership is becoming more comfortable with high-leverage global financing to achieve scale.

Kallianpur further said large acquisitions require sustained management focus and careful capital allocation, particularly as companies balance integration with ongoing investments in research and development.

Sun Pharma has entered into a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion, marking the largest overseas acquisition by an Indian pharmaceutical company. The offer price of $14.00 per share represents a 24% premium. The deal, approved by the boards of both companies, which were advised by JP Morgan, Jefferies, Morgan Stanley, and Goldman Sachs, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.